144699-06-9

Basic information

• Product Name: 1,25-dihydroxy-19-norprevitamin D3
• Synonyms: 1,25-dihydroxy-19-norprevitamin D3
• CAS NO: 144699-06-9
• Molecular Formula: C₂₆H₄₂O₃
• Molecular Weight: 402.60988
• Mol File: 144699-06-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,25-dihydroxy-19-norprevitamin D3(CAS DataBase Reference)
• NIST Chemistry Reference: 1,25-dihydroxy-19-norprevitamin D3(144699-06-9)
• EPA Substance Registry System: 1,25-dihydroxy-19-norprevitamin D3(144699-06-9)

Safety Data

• Hazardous Substances Data: 144699-06-9(Hazardous Substances Data)

Usage

Chemical structure

A synthetic analogue of Vitamin D3 with a modified structure, specifically lacking a carbon atom at the 19th position.

Potency

Increased potency compared to natural Vitamin D3.

Stability

Enhanced stability compared to natural Vitamin D3.

Function

Acts as a powerful regulator of calcium and phosphorus metabolism in the body.

Medical use

Primarily used in the treatment of conditions related to Vitamin D deficiency, such as osteoporosis and hypocalcemia.

Mechanism of action

Binds to Vitamin D receptors in the intestines, bones, and kidneys.

Effects on absorption

Leads to increased absorption of calcium and phosphate.

Bone regulation

Regulates bone mineralization.

Immunomodulatory effects

Exhibits immunomodulatory properties.

Therapeutic potential

May have potential therapeutic applications in various autoimmune and inflammatory conditions.

Pharmaceutical importance

An important pharmaceutical compound with diverse physiological effects, particularly related to bone health and mineral metabolism.

Upstream product

• 70550-73-1 (1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-2-yl]-7a-methyloctahydroinden-4-one 
• 144717-32-8 (R)-6-{(1R,3aR,7aR)-4-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-cyclohex-1-enylethynyl]-7a-methyl-2,3,3a,6,7,7a-hexahydro-1H-inden-1-yl}-2-methyl-heptan-2-ol 
• 144699-09-2 (3S,4S,5S)-3,5-bis(tert-butyldimethylsilyloxy)-1-hydroxymethyl-4-phenoxythiocarbonyloxycyclohex-1-ene 
• 139619-80-0 (1R,6R,7R)-7-[(R)-6-(methoxymethoxy)-6-methylheptan-2-yl]-6-methylbicyclo[4.3.0]nonan-2-one 
• 134458-36-9 25-hydroxy-de-A,B-cholest-8-en-8-yl trifluoromethanesulfonate 
• 101906-40-5 methyl (3S,4S,5S)-3,5-bis(tert-butyldimethylsilyloxy)-4-phenoxythiocarbonyloxycyclohex-1-enecarboxylate 
• 101906-39-2 Methyl (3R,4R,5R)-3,5-Bis<(tert-butyl)dimethylsilyloxy>-4-hydroxycyclohex-1-ene-1-carboxylate 
• 40983-58-2 methyl shikimate 
• 262594-22-9 methyl (3S,5R)-3,5-di[(tert-butyldimethylsilyl)oxy]-cyclohex-1-enecarboxylate 
• 144699-11-6 (3S,5S)-3,5-bis(tert-butyldimethylsilyloxy)cyclohex-1-enecarbaldehyde 
• 144699-08-1 3,5-di[(tert-butyldimethylsilyl)oxy]-1-ethynylcyclohex-1-ene 
• 144699-10-5 (3S,5S)-3,5-bis(tert-butyldimethylsilyloxy)-1-hydroxymethylcyclohex-1-ene 
• 139356-33-5 (3S,5S)-3,5-bis[(tert-butyl)dimethylsilyloxy]-1-hydroxycyclohexane-1-carboxylic acid methyl ester 
• 77-95-2 D-(-)-quinic acid 

Relevant articles and documents

Synthesis, biological activity, and conformational analysis of CD-ring modified trans-decalin 1α,25-dihydroxyvitamin D analogs

A novel series of analogs of 1.25-dihydroxyvitamin D3, the hormonally active metabolite of vitamin D3, characterised by the presence of a trans-fused decalin CD-ring system, possesses surprising biological activities in combination w

Synthesis of two 6-s-cis locked stereoisomeric analogues of the steroid hormone 1α,25-dihydroxyvitamin D3: 1 α,25-dihydroxy-19-nor-previtamin D3 and 1β,25-dihydroxy- 19-nor-previtamin D3

An efficient synthesis of A-ring precursors 8 and 9 from inexpensive commercially available (-)-quinic acid has been developed. A-Ring synthon 8 has been obtained through a short sequence (eight steps) in high overall yield (30%). One key step in the synt

Synthesis of 1α,25-Dihydroxy-19-norprevitamin D3

We describe a convergent synthesis of 1α,25-dihydroxy-19-norprevitamin D3 (3), an analogue of the hormone 1α,25-dihydroxyvitamin D3 (1c), that is locked into the previtamin form.